CompletedPhase 4

Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain

China203 participantsStarted 2020-08-14

Plain-language summary

The total incidence of abdominal pain after colonoscopy is almost 50%. Butorphanol is a mixed opioid receptor agonist-antagonist, which has strong sedative and analgesic effects. This clinical study aims to explore the effectiveness and safety of butorphanol combined with propofol for colonoscopy to reduce postoperative visceral pain, and provide a basis for improving the quality of surgery and comfortable medical treatment for patients.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ASA status I-11 * patients performing colonoscopy * sign the informed consent Exclusion Criteria: * BMI\>30, pregnant * diabetes * depression * patients dependent on opioids * hypertension poorly controlled * serious complications of important organs * obvious abdominal pain before colonoscopy

What they're measuring

visceral pain

Timeframe: 10 minutes after recovery

Trial details

NCT IDNCT04477733

SponsorBeijing Tiantan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-09-30

View on ClinicalTrials.gov More Colonoscopy trials